FDA Accepts Targanta's Oritavancin NDA
Posted on: Thursday, 10 April 2008, 09:01 CDT
Targanta Therapeutics has announced that the FDA has accepted for standard review its new drug application for its lead antibiotic candidate, oritavancin.
By granting standard review status to oritavancin, the FDA has established a target date to act on the new drug application (NDA) filing by December 8, 2008. The oritavancin NDA was submitted in early February seeking approval of the intravenous antibiotic for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus.
Mark Leuchtenberger, president and CEO of Targanta, said: "We are on track to submit a marketing authorization application for EU approval of oritavancin by mid-2008 for the treatment of complicated skin and soft tissue infections, the European name for cSSSI, and, given our preliminary discussions with EU regulatory authorities and standard review times, we hope to receive approval of oritavancin in the EU in late 2009."
Source: Datamonitor
Related Articles
- URAC Open Public Comment Period for New Independent Review Organization Standards
- Merz Pharmaceuticals' Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA
- Microsoft’s OOXML Receives Standardization Approval
- FDA to Review FHC's Premarket Approval Application for Female Condom
- Experts Available to Discuss Cyber-Security Standards Approved for Electric Industry
- Las Vegas Review-Journal Standardizes on ConSentry Secure Switches
- IRRC Approves State-Specific Plan to Control Toxic Mercury Emissions
- EQB Approves State-Specific Plan to Control Toxic Mercury Emissions
- St. Louis Federal Judge Orders EPA to Review Lead Standards
- Atc Its Cabinet and 2070 Standards Approved
 |
 |
User Comments (0)
RSS Feeds